10x Genomics Overview

  • Year Founded
  • 2012

Year Founded

  • Status
  • Public

  • Employees
  • 1,178

Employees

  • Stock Symbol
  • TXG

Stock Symbol

  • Investments
  • 8

  • Share Price
  • $57.40
  • (As of Thursday Closing)

10x Genomics General Information

Description

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives operates from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).

Contact Information

Formerly Known As
10x Technologies, Avante Biosystems
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 6230 Stoneridge Mall Road
  • Pleasanton, CA 94588-3260
  • United States
+1 (925)
Primary Industry
Biotechnology
Stock Exchange
NAS
Corporate Office
  • 6230 Stoneridge Mall Road
  • Pleasanton, CA 94588-3260
  • United States
+1 (925)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

10x Genomics Stock Performance

As of 19-Nov-2026, 10x Genomics’s stock price is $57.40. Its current market cap is $7.55B with 132M shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$57.40 $57.07 $15.18 - $102.81 $7.55B 132M 3.36M -$0.52

10x Genomics Financials Summary

As of 30-Sep-2026, 10x Genomics has a trailing 12-month revenue of $619M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 11,299,873 1,668,981 1,426,059 6,356,519
Revenue 618,576 642,823 610,785 618,727
EBITDA (39,587) (16,139) (152,918) (221,996)
Net Income (67,078) (43,544) (182,627) (255,099)
Total Assets 1,063,129 1,041,365 918,636 965,143
Total Debt 75,792 84,361 82,613 95,370
Public Fundamental Data provided by Morningstar, Inc. disclaimer

10x Genomics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore 10x Genomics‘s full profile, request access.

Request a free trial

10x Genomics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore 10x Genomics‘s full profile, request access.

Request a free trial

10x Genomics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, con
Biotechnology
Pleasanton, CA
1,178 As of 2025

Minneapolis, MN
 

Boston, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

10x Genomics Competitors (21)

One of 10x Genomics’s 21 competitors is Bio-Techne, a Corporation company based in Minneapolis, MN.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Bio-Techne Corporation Minneapolis, MN
Standard BioTools Formerly VC-backed Boston, MA
CD Genomics Corporation Shirley, NY
GSK Corporation London, United Kingdom
Qiagen Formerly VC-backed Hilden, Germany
You’re viewing 5 of 21 competitors. Get the full list »

10x Genomics Patents

10x Genomics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20260308572-A1 Analysis of cellular samples Pending 02-Apr-2025
US-20260258490-A1 Methods and compositions for probe rescue Pending 03-Mar-2025
WO-2026178257-A1 De-crosslinking for multi analyte analysis Pending 20-Feb-2025
WO-2026165121-A1 Rolling circle methods using primers binding to barcode sequences for amplification and related compositions Pending 29-Jan-2025
WO-2026148062-A2 Compositions and methods for analysis of cellular analytes Pending 31-Dec-2024 C12Q1/6841
To view 10x Genomics’s complete patent history, request access »

10x Genomics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

10x Genomics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore 10x Genomics‘s full profile, request access.

Request a free trial

10x Genomics Investments & Acquisitions (8)

10x Genomics’s most recent deal was a Merger/Acquisition with Proteintech (Proteintech Genomics). The deal was made on 09-Jun-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Proteintech (Proteintech Genomics) 09-Jun-2026 Merger/Acquisition Biotechnology
Scale Biosciences 11-Aug-2025 Merger/Acquisition Biotechnology
Centrillion Technologies (Certain Intangible and Other Assets) 14-Jul-2023 Corporate Asset Purchase Buildings and Property
Tetramer Shop 08-Jan-2021 Merger/Acquisition Discovery Tools (Healthcare)
ReadCoor 13-Oct-2020 Merger/Acquisition Discovery Tools (Healthcare)
You’re viewing 5 of 8 investments and acquisitions. Get the full list »

10x Genomics ESG

Risk Overview

Risk Rating

Updated November, 17, 2026

20.4 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Laboratory Equipment and Services

Subindustry

of 67

Rank

Percentile

To view 10x Genomics’s complete esg history, request access »

10x Genomics Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Scale Biosciences San Diego, CA 2020

10x Genomics FAQs

  • When was 10x Genomics founded?

    10x Genomics was founded in 2012.

  • Where is 10x Genomics headquartered?

    10x Genomics is headquartered in Pleasanton, CA.

  • What is the size of 10x Genomics?

    10x Genomics has 1,178 total employees.

  • What industry is 10x Genomics in?

    10x Genomics’s primary industry is Biotechnology.

  • Is 10x Genomics a private or public company?

    10x Genomics is a Public company.

  • What is 10x Genomics’s stock symbol?

    The ticker symbol for 10x Genomics is TXG.

  • What is the current stock price of 10x Genomics?

    As of 19-Nov-2026 the stock price of 10x Genomics is $57.40.

  • What is the current market cap of 10x Genomics?

    The current market capitalization of 10x Genomics is $7.55B.

  • What is 10x Genomics’s current revenue?

    The trailing twelve month revenue for 10x Genomics is $619M.

  • Who are 10x Genomics’s competitors?

    Bio-Techne, Standard BioTools, CD Genomics, GSK, and Qiagen are some of the 21 competitors of 10x Genomics.

  • What is 10x Genomics’s annual earnings per share (EPS)?

    10x Genomics’s EPS for 12 months was -$0.52.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process